ARDX
Ardelyx, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Last price
3.92
▲ 0.02 (0.51%)
MARKET · —
Price
Open
3.92
Prev close
3.90
Day high
3.97
Day low
3.88
Volume
2.86M
Market cap
$1.00B
P/E (TTM)
—
52W range
3.86 – 8.40
Trailing performance
Returnvs SPY
1W
-4.19%
-2.8%
1M
-24.17%
-27.9%
3M
-38.74%
-41.8%
6M
-32.11%
-43.2%
YTD
-33.28%
-45.6%
1Y
-35.06%
-55.1%
3Y
+4.57%
-69.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$1.00B
Enterprise value$970.02M
Revenue (TTM)$450.89M
Gross profit$338.28M
EBITDA$-32.11M
Net income$-55.70M
EPS (TTM)$-0.23
Free cash flow$20.47M
Total cash$281.83M
Total debt$282.51M
Book value / share$0.60
Shares outstanding258.19M
Float210.54M
Short % of float10.76%
Dividend yield—
Beta (5Y)0.73
Valuation & profitability ratios
Trailing P/E—
Forward P/E15.44
PEG ratio—
Price / sales—
Price / book6.51
EV / revenue2.15
EV / EBITDA-30.21
Gross margin75.02%
Operating margin-10.28%
Profit margin-12.35%
Return on equity-38.61%
Return on assets-4.25%
Debt / equity189.59
Current ratio3.34
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $407.32M | $333.62M | $124.46M | $52.16M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$61.60M | -$39.14M | -$66.07M | -$67.21M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$61.60M | -$39.14M | -$66.07M | -$67.21M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.05 | -0.07 | -41.4% |
| Mar 2026 | -0.14 | -0.15 | -5.0% |
| Dec 2025 | 0.01 | 0.00 | -100.0% |
| Sep 2025 | -0.07 | 0.00 | +100.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.02 | 7 | $129.22M | +17.1% |
| Next quarter | 0.03 | 7 | $144.19M | +15.2% |
| Current year | -0.20 | 7 | $488.78M | +20.0% |
| Next year | 0.25 | 7 | $623.90M | +27.6% |
Analyst targets & ownership
Mean target$12.90
High target$18.00
Low target$8.00
Implied upside229.08%
Analyst count10
ConsensusSTRONG BUY
Strong buy / Buy1 / 10
Hold0
Sell / Strong sell0 / 0
Held by insiders3.23%
Held by institutions73.33%
Institutions holding332
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+202.00K
Net buying
Buy transactions
15
707.14K shares
Sell transactions
23
505.14K shares
Net transactions
+38
Buys less sells
Sell : buy shares
0.7 : 1
Mixed
Insider-held shares
8.05M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 15, 26 | RAAB MICHAEL G Chief Executive Officer |
SELL | 41.67K | $210.92K | Direct |
| Jul 15, 26 | RAAB MICHAEL G Chief Executive Officer |
CONVERSION | 20.83K | $20.63K | Direct |
| Jun 18, 26 | WILLIAMS LAURA A Officer |
SELL | 81.90K | $490.49K | Direct |
| Jun 18, 26 | WILLIAMS LAURA A Officer |
CONVERSION | 31.00K | $30.69K | Direct |
| Jun 16, 26 | MOTT DAVID M Director |
STOCK | 46.74K | $0 | Direct |
| Jun 16, 26 | PARSEY MERDAD V Director |
STOCK | 26.45K | $0 | Direct |
| Jun 16, 26 | CADORET-MANIER ONAIZA Director |
STOCK | 26.45K | $0 | Direct |
| Jun 16, 26 | BHANJI MUNA Director |
STOCK | 26.45K | $0 | Direct |
| Jun 16, 26 | BERTRAND WILLIAM C JR Director |
STOCK | 38.80K | $0 | Direct |
| Jun 16, 26 | RODGERS RICHARD J. Director |
STOCK | 26.45K | $0 | Direct |
| Jun 16, 26 | BAZEMORE ROBERT B Director |
STOCK | 26.45K | $0 | Direct |
| Jun 15, 26 | RAAB MICHAEL G Chief Executive Officer |
SELL | 41.67K | $236.35K | Direct |
| Jun 15, 26 | RAAB MICHAEL G Chief Executive Officer |
CONVERSION | 20.83K | $20.63K | Direct |
| May 21, 26 | BISHOP JOHN E Officer |
SELL | 2.31K | $14.45K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BERTRAND WILLIAM C JR |
Director | 329.51K | Stock Award(Grant) |
BISHOP JOHN E |
Officer | 336.85K | Sale |
FOSTER ERIC DUANE |
Officer | 417.97K | Sale |
KELLIHER MICHAEL |
Officer | 357.42K | Sale |
MOTT DAVID M |
Director | 3.35M | Stock Award(Grant) |
RAAB MICHAEL G |
Chief Executive Officer | 1.70M | Sale |
RENZ JUSTIN ANDREW |
Chief Financial Officer | 409.05K | Sale |
RODGERS RICHARD J. |
Director | 440.00K | Stock Award(Grant) |
ROSENBAUM DAVID PAUL |
Officer | — | Sale |
WILLIAMS LAURA A |
Officer | 378.19K | Sale |
Moving averages & technicals
SMA 10
3.97
-1.21% from price
SMA 20
4.43
-12.17% from price
SMA 50
5.05
-22.99% from price
SMA 100
5.62
-30.20% from price
SMA 200
5.96
-34.69% from price
EMA 12
4.13
-5.01% from price
EMA 26
4.48
-12.52% from price
EMA 50
4.89
-19.88% from price
RSI (14)
26.9
Oversold
MACD (12,26,9)
-0.35
Hist -0.02
ATR (14)
0.23
5.99% of price
Realised vol 30D
61.9%
Annualised
Bollinger upper
5.45
20, 2σ
Bollinger lower
3.41
20, 2σ
50 / 200 cross
Death
5.05 vs 5.96
Trend bias
Below 200
-34.69%
Risk profile
Beta vs SPY
0.82
Less volatile than market
Correlation to SPY
0.17
Largely independent
Realised vol 30D
61.9%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-51.3%
Peak to trough
Max drawdown 5Y
-70.0%
Peak to trough
ATR 14
0.23
5.99% of price
Beta (reported)
0.73
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
2.15
Put-heavy session
Put / call open interest
0.16
Positioning, not flow
Max pain
5.00
+28.5% from spot
ATM implied vol
63.7%
Nearest strike to spot
Skew (10% OTM)
-8.2%
Calls bid over puts
Call volume
118
Contracts, this expiry
Put volume
254
Contracts, this expiry
Heaviest call OI
5.00
1.93K contracts
Heaviest put OI
4.00
383 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Valeris Welcomes Patient Services Veteran Lauren Cole to Lead Commercial Strategy
PR Newswire · 4d ago
Ardelyx (ARDX) Q2 2026 Earnings Call Transcript
Motley Fool · 9d ago
Ardelyx (ARDX) Is Down 19.7% After Raising IBSRELA Revenue Guidance And Narrowing Losses
Simply Wall St. · 12d ago
Ardelyx (ARDX) Posts Record Revenue, Is The Stock Still 70% Undervalued?
Simply Wall St. · 15d ago
Wedbush Adjusts Price Target on Ardelyx to $9 From $19, Maintains Outperform Rating
MT Newswires · 15d ago
New Strong Sell Stocks for August 7th
Zacks · 15d ago
Ardelyx Inc (ARDX) (Q2 2026) Earnings Call Highlights: Record Revenue of $118M Driven by Strong ...
GuruFocus.com · 16d ago
Ardelyx (ARDX) Reports Q2 Loss, Lags Revenue Estimates
Zacks · 16d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.